Skip to main content

Omnicell Value Stock - Dividend - Research Selection

Omnicell

ISIN: US68213N1090 , WKN: 632313

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Wells Fargo Maintains Overweight on Omnicell, Lowers Price Target to $50

2026-07-31
Wells Fargo analyst Stan Berenshteyn maintains Omnicell (NASDAQ:OMCL) with a Overweight and lowers the price target from $55 to $50.

Keybanc Maintains Overweight on Omnicell, Lowers Price Target to $65

2026-07-31
Keybanc analyst Scott Schoenhaus maintains Omnicell (NASDAQ:OMCL) with a Overweight and lowers the price target from $70 to $65.

Omnicell, Inc. 2026 Q2 - Results - Earnings Call Presentation

2026-07-30
2026-07-30. The following slide deck was published by Omnicell, Inc.

Omnicell, Inc. (OMCL) Q2 2026 Earnings Call Transcript

2026-07-30
Omnicell, Inc. (OMCL) Q2 2026 Earnings Call July 30, 2026 8:30 AM EDTCompany ParticipantsDavid UngerRandall Lipps - Founder, Executive Chairman &...

Omnicell (NASDAQ:OMCL) Q2 Earnings Beat Overshadowed by Disappointing Guidance

2026-07-30
Omnicell Q2 earnings beat estimates sharply but revenue slightly missed; cautious Q3 and full-year guidance drove pre-market drop of ~3.4%.

Omnicell Sees Q3 Adj EPS $0.35-$0.43 vs $0.47 Est; Sees Sales $301.000M-$307.000M vs $312.528M Est

2026-07-30
Omnicell (NASDAQ:OMCL) is looking for Q3 Adj EPS of $0.35-$0.43 vs $0.47 analyst estimate. sees sales of $301.000 million-$307.000 million vs $312.528 million analyst estimate.

Omnicell Raises FY2026 Adj EPS Guidance from $1.80-$2.00 to $2.15-$2.30 vs $1.94 Est; Narrows FY2026 Sales Guidance from $1.215B-$1.255B to $1.225B-$1.245B vs $1.248B Est

2026-07-30
Omnicell (NASDAQ:OMCL) raises FY2026 Adj EPS guidance from $1.80-$2.00 to $2.15-$2.30 vs $1.94 analyst estimate. Narrows FY2026 sales outlook from $1.215 billion-$1.255 billion to $1.225 billion-$1.245 billion vs $1.248

Omnicell Q2 Adj. EPS $0.94 Beats $0.47 Estimate, Sales $312.208M Beat $310.253M Estimate

2026-07-30
Omnicell (NASDAQ:OMCL) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.47 by 100 percent. This is a 108.89 percent increase over earnings of $0.45 per share from the same

Nvidia, Teradyne, and Omnicell Earnings Set to Test Robotics Sector’s Divergent Momentum

2026-07-23
Robotics and automation stocks enter a high-conviction earnings week with key reports from NVIDIA, Teradyne, and Omnicell. These results will test sector momentum amid strong fundamentals and mixed price action.

The Bull Case For Omnicell (OMCL) Could Change Following New President And ESOP Share Offering

2026-07-13
Earlier this month, Omnicell filed a US$72.384 million shelf registration for 1,600,000 common shares tied to an ESOP-related offering and elevated Chief Operating Officer Nnamdi Njoku to President, while Randall Lipps remained Chief Executive Officer and Chairman. This combination of leadership evolution and employee-focused equity issuance may influence how investors assess Omnicell’s governance, culture, and long-term execution capacity. We’ll now examine how Njoku’s expanded leadership...